Uveitis Therapeutics in Asia-Pacific Markets Expected to Register CAGR of 12.4% by 2023, Novel Pipeline Drugs to Drive Growth

Published on : Mar 19, 2018

Albany, New York, March 19, 2018: There is an increasing number of people being affected by uveitis annually. It is a leading cause of blindness in both developed and developing countries and is the fifth most common cause of vision loss in the developed world. Recently, a new study titled “Uveitis Therapeutics in Asia-Pacific Markets to 2023” has been publicized to the wide repository of Market Research Hub (MRH), which offers the detailed overview of the current uveitis therapeutic market scenario along with future growth prospects until the end of 2023. The readers will also be able to understand the current clinical and commercial landscape through a comprehensive analysis of disease symptoms, diagnostic methods, etiology, pathophysiology, epidemiology, prognosis and treatment.

Research Snapshot and Key Findings

With a prime focus on Asia Pacific market, the research throws lights on key factors driving the uveitis therapeutic market. Various drivers and barriers that will influence the market over the forecast period are also included in the study. The research forecasts market growth across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth. As per the research findings, the Asia-Pacific uveitis market was valued at $179m in 2016 and is expected to be worth $405.5m by the end of 2023. During the forecast period of 2018-2023, the market is expected to register a noteworthy CAGR of 12.4%.

Uveitis is a form of eye inflammation. Untreated or under-treated uveitis, or repeated episodes of inflammation within the eye, can lead to scarring and blinding consequences, if not given the right treatment and medication. It has been analyzed that Uveitis represents a major cause of ocular morbidity worldwide and often results in complications such as cataracts, glaucoma, ocular hypertension, macular issues, and retinal detachment.

The report starts with the executive summary that includes pipeline landscape and stratifies pipeline therapies by stage of development, molecule type and molecular target. Also, the uveitis market is characterized by a small selection of marketed drug options, consisting of corticosteroid therapies, immunosuppressive therapies and biologics. It has been noted that currently, only one targeted therapy is available in the Asia-Pacific uveitis market, which is AbbVie’s Humira (adalimumab).

As the report proceeds, the research presents analysis on marketed products and available drugs offered by companies. The analyst observes that new drugs will expand the options available to treat uveitis patients and contribute to overall market growth by offering novel treatment mechanisms, including new drug delivery routes and novel, non-corticosteroid drug molecules. Apart from the above-mentioned information, the research study also visualizes the composition of the uveitis market in terms of dominant therapies, with their clinical and commercial standing.

Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1641312

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top